Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul;24(7):215-224.
doi: 10.1007/s11906-022-01177-6. Epub 2022 Apr 30.

The Time to Reconsider Mineralocorticoid Receptor Blocking Strategy: Arrival of Nonsteroidal Mineralocorticoid Receptor Blockers

Yuta Tezuka  1 , Sadayoshi Ito  2   3
Affiliations
Review

The Time to Reconsider Mineralocorticoid Receptor Blocking Strategy: Arrival of Nonsteroidal Mineralocorticoid Receptor Blockers

Yuta Tezuka et al. Curr Hypertens Rep. 2022 Jul.

Abstract

Purpose of review: The study aims to verify the advantages of nonsteroidal mineralocorticoid receptor blockers (MRBs) in the management of hypertension and cardiovascular and renal diseases, comparing with conventional MRBs.

Recent findings: Based on the unique structures, the nonsteroidal MRBs have higher selectivity for mineralocorticoid receptors (MRs) and show no agonist activity for major steroid hormone receptors in contrast to steroidal MRBs. Today, there are two nonsteroidal MRBs, esaxerenone and finerenone, which completed phase 3 clinical trials. Series of clinical trials have shown that both agents achieve similar MR blockade with smaller doses as compared with steroidal MRBs, but have no off-target side effect such as gynecomastia. Esaxerenone has persistent blood pressure-lowering effects in various hypertensive populations, including essential hypertension and those with diabetes and/or chronic kidney disease, while finerenone has demonstrated reduction of the cardiovascular risk rather than blood pressure in patients with diabetes and chronic kidney disease. Nonsteroidal MRBs are a more refined agent which contributes to appropriate MR blocking with minimized unpleasant adverse effects.

Keywords: Esaxerenone; Finerenone; Hypertension; Mineralocorticoid receptor; Nonsteroidal mineralocorticoid receptor blocker.

PubMed Disclaimer

Conflict of interest statement

Yuta Tezuka and Sadayoshi Ito declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Molecular structures of steroids and mineralocorticoid receptor blockers. The structures of steroidal and nonsteroidal mineralocorticoid receptor blockers (MRBs) are shown, compared with aldosterone, a representative mineralocorticoid in human, and progesterone. Spironolactone was generated by mimicking the structure of progesterone, while eplerenone was developed to improve the selectivity of spironolactone for mineralocorticoid receptors. Nonsteroidal MRBs are relatively “bulky” and quite distinct molecules from those steroidal agents
Fig. 2
Fig. 2
Binding mode of mineralocorticoid receptor blockers to mineralocorticoid receptors. Mineralocorticoids (A) and mineralocorticoid receptor blockers (MRBs; B and C) bind to mineralocorticoid receptors (MRs) in the cytoplasm. (A) The complexes of a mineralocorticoid and a MR form a homodimer after translocation into the nucleus. Then, the homodimer complex binds to the hormone responsive element (HRE) of the target gene, leading to DNA transcription supported by co-activators (Co-A). (B) Steroidal MRBs prevent mineralocorticoids from binding to MRs, but themselves have partial agonist activity for MRs. Therefore, steroidal MRBs could also somewhat prompt transcription of the target gene. (C) Due to the “bulky” structure, nonsteroidal MRBs alter the shape of MR when binding. This modified MR complex precludes not only mineralocorticoid binding but also the recruitment of co-activators, resulting in inhibition of MR signaling
See this image and copyright information in PMC

References

    1. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059–2068. doi: 10.1016/S0140-6736(15)00257-3. - DOI - PMC - PubMed
    1. Serenelli M, Jackson A, Dewan P, Jhund PS, Petrie MC, Rossignol P, et al. Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction. JACC Heart Fail. 2020;8(3):188–198. doi: 10.1016/j.jchf.2019.09.011. - DOI - PMC - PubMed
    1. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21. doi: 10.1056/NEJMoa1009492. - DOI - PubMed
    1. Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol. 2018;6(6):464–475. doi: 10.1016/S2213-8587(18)30071-8. - DOI - PMC - PubMed
    1. Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) J Am Coll Cardiol. 2013;62(17):1585–1593. doi: 10.1016/j.jacc.2013.04.086. - DOI - PubMed

MeSH terms

Substances